MedTrace Logo

Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity

NCT04226456 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-10-24

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.

Conditions

  • Ototoxic Hearing Loss
  • Ototoxic Hearing Loss, Bilateral
  • Ototoxicity
  • Tinnitus

Interventions

DRUG

N-acetyl cysteine

Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Saint Pierre

    lead OTHER

Principal Investigators

  • Gaëtan Cavelier, MD · Centre Hospitalier Universitaire Saint Pierre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-10
Primary Completion
2023-05-03
Completion
2023-09-03

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226456 on ClinicalTrials.gov